Company Of The Day: Merck
What?
The Wall Street Journal reports that Merck (NYSE:MRK) is looking to buy Acceleron Pharma, in a deal that could be announced as soon as this week.
Why?
Relevant Articles
- Will Higher Keytruda Sales Drive Merck’s Q1
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- At $100 Does Merck Stock Have Room For Growth?
- Should You Pick Merck Stock Over Coca-Cola?
- Should You Buy Merck Stock After An Upbeat Q2?
- How Has Merck Stock Performed During The 2022-23 Inflation Shock?
A deal could bolster Merck’s rare diseases business. Acceleron’s most high-profile development is an experimental drug for pulmonary arterial hypertension, a respiratory disease.
So What?
While the deal would be one of Merck’s largest ever, it probably isn’t too big in the context of Merck’s market cap. XLRN had a market cap of about $11 billion as of Monday, compared to MRK’s $185 billion market cap.
See Our Complete Analysis For Merck
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates